Search research articles
Contact Us
Filters
Showing results (31-40 of 376) with videos related to
Page
of 38
Sort By:
Antimicrobial Agents and Chemotherapy
|
November 15, 2011
Determination of meropenem penetration into the lung from Sparse data
Martin G Kees, Thomas P Lodise, G L Drusano
Lancet (London, England)
|
September 2, 2017
Very low LDL-cholesterol concentrations achieved: which target is next?
G Kees Hovingh, S Matthijs Boekholdt, Erik S Stroes
European Journal of Preventive Cardiology
|
November 23, 2019
PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia
Laurens F Reeskamp, Tycho R Tromp, G Kees Hovingh
The Journal of Antimicrobial Chemotherapy
|
July 7, 2011
Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients
Martin G Kees, Susanne Weber, Frieder Kees, et al.
Journal of the American College of Cardiology
|
May 23, 2020
Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans
John J P Kastelein, Laurens F Reeskamp, G Kees Hovingh
Expert Opinion on Investigational Drugs
|
May 1, 2020
Gene-based therapy in lipid management: the winding road from promise to practice
Tycho R Tromp, Erik S G Stroes, G Kees Hovingh
European Heart Journal
|
October 12, 2017
Homozygous familial hypercholesterolaemia: light at the end of the tunnel
Robert M Stoekenbroek, G Kees Hovingh, John J P Kastelein
Nature Reviews. Endocrinology
|
October 28, 2018
Inhibiting PCSK9 - biology beyond LDL control
Robert M Stoekenbroek, Gilles Lambert, Bertrand Cariou, et al.
Journal of the American College of Cardiology
|
April 25, 2020
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar
David Preiss, Jonathan A Tobert, G Kees Hovingh, et al.
European Heart Journal
|
April 27, 2017
Can we afford not to screen for FH?
Robert M Stoekenbroek, John J P Kastelein, G Kees Hovingh
Page
of 38
Search research articles
Search
Showing results (31-40 of 376) with videos related to
Sort By:
Page
of 38
Antimicrobial Agents and Chemotherapy
|
November 15, 2011
Determination of meropenem penetration into the lung from Sparse data
Martin G Kees, Thomas P Lodise, G L Drusano
Lancet (London, England)
|
September 2, 2017
Very low LDL-cholesterol concentrations achieved: which target is next?
G Kees Hovingh, S Matthijs Boekholdt, Erik S Stroes
European Journal of Preventive Cardiology
|
November 23, 2019
PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia
Laurens F Reeskamp, Tycho R Tromp, G Kees Hovingh
The Journal of Antimicrobial Chemotherapy
|
July 7, 2011
Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients
Martin G Kees, Susanne Weber, Frieder Kees, et al.
Journal of the American College of Cardiology
|
May 23, 2020
Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans
John J P Kastelein, Laurens F Reeskamp, G Kees Hovingh
Expert Opinion on Investigational Drugs
|
May 1, 2020
Gene-based therapy in lipid management: the winding road from promise to practice
Tycho R Tromp, Erik S G Stroes, G Kees Hovingh
European Heart Journal
|
October 12, 2017
Homozygous familial hypercholesterolaemia: light at the end of the tunnel
Robert M Stoekenbroek, G Kees Hovingh, John J P Kastelein
Nature Reviews. Endocrinology
|
October 28, 2018
Inhibiting PCSK9 - biology beyond LDL control
Robert M Stoekenbroek, Gilles Lambert, Bertrand Cariou, et al.
Journal of the American College of Cardiology
|
April 25, 2020
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar
David Preiss, Jonathan A Tobert, G Kees Hovingh, et al.
European Heart Journal
|
April 27, 2017
Can we afford not to screen for FH?
Robert M Stoekenbroek, John J P Kastelein, G Kees Hovingh
Page
of 38